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The incidence of prostate cancer varies widely, with Western
countries having rates 30–50 times higher than those in Far-
Eastern countries (Parkin et al, 1992) and it is now the commonest
incident cancer and the second most common cause of cancer
mortality in North American men (Parker et al, 1996). The reasons
for the wide differences in prostate cancer incidence between
populations are not yet established, but the fact that an increase in
prostate cancer has been seen among Asian migrants to the USA
(Shimizu et al, 1991) suggests that environmental or lifestyle
factors are important. However, other than race, age and a family
history of prostate cancer (Nomura and Kolonel, 1991), aetiolog-
ical risk factors remain largely unknown, although it has been
suggested that the adoption of Western dietary habits with a high
fat and/or low plant food consumption may be associated with
prostate cancer risk (Adlercreutz, 1990). Furthermore, it has been
postulated that dietary factors may exert their effects by altering
sex hormone metabolism, and that this may play a significant role
in the progression of latent lesions into clinically relevant cancer
(Montie and Pienta, 1994).
Many epidemiological studies have been conducted over the
last 20 years in an attempt to identify differences in sex hormone
metabolism between prostate cancer patients and controls, and in
individuals from high- and low-risk populations, by measuring
differences in serum hormone levels. The evidence from case-
control studies that circulating hormone levels are related to
prostate cancer is inconsistent (Flanders, 1986), and these studies
suffer from the problem that disease status may well alter serum
concentrations of androgens. As such, it is impossible to interpret
any differences present in serum levels between cases and controls
in relation to the aetiology of the disease. Prospective studies
reduce the possibility that changes in hormone levels are due to
disease status as blood samples are taken some years prior to diag-
nosis. This paper presents a quantitative review (meta-analysis)
of the published data from prospective studies which compared
serum concentrations of sex hormones in men who subsequently
developed prostate cancer with those in men who remained cancer
free.
MATERIALS AND METHODS
Papers were identified by searching the Medline database,
1966–1998, using combinations of the following keywords:
hormones; androgens; prostate cancer; prospective; serum. The
reference lists of the relevant papers were also examined. Ten
papers reporting results from eight prospective studies were identi-
fied for inclusion in this meta-analysis, of which seven were
nested case-control studies where controls were chosen according
to specific matching criteria (Nomura et al, 1988, 1996; Comstock
et al, 1993; Hsing and Comstock, 1993; Carter et al, 1995; Gann et
al, 1996; Guess et al, 1997; Vatten et al, 1997; Dorgan et al, 1998)
and one was a cohort study in which the controls were all partici-
pants with no diagnosis of prostate cancer (Barrett-Connor et al,
1990). Two papers (Nomura et al, 1988; Comstock et al, 1993)
include cases that are a subset of the prostate cancer cases
described in other papers (Nomura et al, 1996; Hsing and
Comstock, 1993), but are included in this review as they have
analysed different hormones.
Table 1 shows the characteristics of the study populations. All
studies, except Barrett-Connor et al (1990), included matching for
Review
Endogenous sex hormones and prostate cancer:
a quantitative review of prospective studies
NE Eaton, GK Reeves, PN Appleby and TJ Key
Imperial Cancer Research Fund, Cancer Epidemiology Unit, Gibson Building, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK
Summary This paper presents a quantitative review of the data from eight prospective epidemiological studies, comparing mean serum
concentrations of sex hormones in men who subsequently developed prostate cancer with those in men who remained cancer free. The
hormones reviewed have been postulated to be involved in the aetiology of prostate cancer: androgens and their metabolites testosterone
(T), non-SHBG-bound testosterone (non-SHBG-bound T), di-hydrotestosterone (DHT), androstanediol glucuronide (A-diol-g),
androstenedione (A-dione), dehydroepiandrosterone sulphate (DHEAS), sex hormone binding globulin (SHBG), the oestrogens, oestrone
and oestradiol, luteinizing hormone (LH) and prolactin. The ratio of the mean hormone concentration in prostate cancer cases to that of
controls (and its 95% confidence interval (CI)) was calculated for each study, and the results summarized by calculating the weighted average
of the log ratios. No differences in the average concentrations of the hormones were found between prostate cancer cases and controls, with
the possible exception of A-diol-g which exhibited a 5% higher mean serum concentration among cases relative to controls (ratio 1.05, 95%
CI 1.00–1.11), based on 644 cases and 1048 controls. These data suggest that there are no large differences in circulating hormones
between men who subsequently go on to develop prostate cancer and those who remain free of the disease. Further research is needed to
substantiate the small difference found in A-diol-g concentrations between prostate cancer cases and controls.
Keywords: prostate cancer; steroid hormones; androstanediol glucuronide; prospective studies; review
930
British Journal of Cancer (1999) 80(7), 930–934
© 1999 Cancer Research Campaign
Article no. bjoc.1999.0445
Received 25 November 1998
Accepted 4 January 1999
Correspondence to: NE EatonA quantitative review of sex hormones and prostate cancer 931
British Journal of Cancer (1999) 80(7), 930–934 © 1999 Cancer Research Campaign 
age. Most populations were predominantly Caucasian, although in
one study the participants were all Japanese-American (Nomura
et al, 1988, 1996), and in another the ethnic composition was
not stated (Carter et al, 1990). Six studies had matched for years
since blood sample was taken (Nomura et al, 1988, 1996; Carter et
al, 1995; Gann et al, 1996; Guess et al, 1997; Vatten et al, 1997;
Dorgan et al, 1998); three for time of day of venipuncture
(Nomura et al, 1988, 1996; Barrett-Connor et al, 1990; Dorgan et
al, 1998); two for previous history of prostatic surgery (Nomura et
al, 1988, 1996; Gann et al, 1996), and two for smoking (Gann et al,
1996; Dorgan et al, 1998).
To present the results in a consistent format, the mean concen-
tration of each hormone for cases and controls was extracted from
the published data, and the ratio of the mean among cases to that of
controls was calculated. Either serum or plasma concentrations
were used, but considering their similarity, they shall be referred to
as serum values. For each individual study, the standard errors of
the means were used to calculate an approximate standard error of
the log ratio. This was then used to obtain a 95% confidence
interval (CI) for the log ratio which was exponentiated to give a
corresponding CI for the ratio. Median values rather than means
were published in three studies, and additional information was
sought from the authors in order to obtain the means and standard
errors for cases and controls.
In order to summarize the results, weighted averages of the study-
specific log ratios were calculated, with weights determined by the
inverse of the variance of each log ratio. The degree of heterogeneity
in the log ratios between individual studies was assessed by c2 tests.
The results are displayed separately for each hormone in figures
1 to 11 where each study-specific estimate of the ratio of the mean
concentration in cases to controls is plotted as a square and its CI is
denoted by the horizontal line crossing through it. The area of each
square is inversely proportional to the variance of the log ratio and
reflects the amount of statistical information available for that
particular estimate. Where the CI extends beyond the scale of
the plot it is indicated by an arrow. The summary estimate (the
weighted average of the log ratios) is plotted as an open diamond,
the horizontal tips of which represent the 95% CI.
Table 1 Characteristics of the study populations and follow-up times for the seven nested case-control studies and one prospective cohort study
Reference Study population Study period Age at Mean years to No. No. Matching criteria
(recruitment to recruitment diagnosis (range) cases controls
end of follow-up) (years)
Nomura et al 6860 participants of the 1971–1996a 45–68 7 (< 1–14)b 141c 141c Age
(1988, 1996) Honolulu Heart Program, Oahu, Ethnicity (Japanese-
Hawaii American)
Date of venipuncture
Time of day of
venipuncture
No prior history of
prostatic surgery
Barrett-Connor et al 1008 participants of the Rancho 1972–1986 40–79 8 (1–14) 57 951 Time of day of
(1990) Bernardo Study, CA, USA venipuncture
Hsing & Comstock 25 620 residents of Washington 1974–1987 35–94 Not given 98d 98d Age
(1993) and County, MD, USA (1–12) Ethnicity (Caucasian)
Comstock et al
(1993)
Carter et al (1995) 1459 participants of the 1958–1990 55–90 Not given 16 16 Age
Baltimore Longitudinal Study (7–25) Date of venipuncture
of Aging, Baltimore, MD, USA
Gann et al (1996) 22 071 participants of the 1982–1992 40–84 6 222 390 Age
Physicians’ Health Study, USA (range not given) Date of venipuncture
No prior history of
prostatic surgery
Smoking
Guess et al (1997) 128 992 participants of the 1964–1987 Not given 14 106 106 Age
Kaiser Permanente Medical (5–23) Ethnicity (Caucasian)
Care Program (KPMCP), US Date of venipuncture
Clinic location
Vatten et al (1997) 28 000 blood donors, 1973–1994 42–66 10 59 180 Age
Oslo, Norway (1–19) Date of venipuncture
Dorgan et al (1998) 29 133 participants of the 1985–1993 50–69 4e 116 231 Age
Alpha-Tocopherol, Beta- (< 1–7) Ethnicity (Caucasian)
Carotene Study (ATBC), Date of venipuncture




aNomura et al (1988) follow-up period: 1971–1984. bNot given in Nomura et al (1988) paper. cNomura et al (1988) included 98 matched case-control pairs which
are a subset of Nomura et al (1996) study population. dComstock et al (1993) included 81 matched case-control pairs which are a subset of Hsing et al (1993)
study population. eMedian given.932 NE Eaton et al
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RESULTS
Figures 1–11 summarize the results of eight prospective studies
which reported the serum concentration of testosterone (T), non-
SHBG bound T, di-hydrotestosterone (DHT), androstanediol
glucuronide (A-diol-g), androstenedione (A-dione), dehy-
droepiandrosterone sulphate (DHEAS), sex hormone binding
globulin (SHBG), oestrone, oestradiol, luteinizing hormone (LH)
and/or prolactin in men who subsequently developed prostate
cancer in comparison to men who remained free of the disease.
Most information was available for T with 817 cases. There was
no evidence that the serum concentration of T was different
between cases and controls, with a pooled ratio of 0.99 (95% CI
0.95–1.02) and there was no evidence of heterogeneity between
the studies. The pooled estimates for the other hormones included
data from between 114 and 644 cases and no significant differ-
ences in mean concentrations between prostate cases and controls
were found. However, all five studies that measured A-diol-g
reported a higher mean concentration among cases relative to
controls which was reflected in the pooled ratio of 1.05 (95% CI
1.00–1.11). Thus, cases had, on average, a 5% higher mean serum
concentration of A-diol-g than controls, based on 644 cases and
1048 controls.
DISCUSSION
This quantitative review reveals no convincing evidence that
serum levels of endogenous sex hormones, their precursor
compounds and metabolites and related binding protein, differ
between men who subsequently go on to develop prostate cancer
and those who do not. The pooled estimate for A-diol-g does,
however, suggest that prostate cancer cases had a 5% higher serum
concentration relative to controls.
Differences in oestradiol levels of approximately 15% have
been found to influence the risk of hormone-sensitive cancers, as
found for breast cancer risk in post-menopausal women (Thomas
et al, 1997). The finding that circulating serum levels of A-diol-g
are 5% higher in prostate cancer cases than controls is consistent
with the hypothesis that elevated hormonal activity is important
in the progression of hormone-sensitive cancers. Circulating
androgen levels are likely to be only weakly correlated with the
hormonal environment within the prostate gland, therefore small
differences in circulating serum levels of A-diol-g may reflect
larger differences in androgen activity within the prostate gland
that are of biological relevance. Elevated A-diol-g concentrations
may reflect an increased transformation from T to DHT within
prostatic tissue, resulting in overstimulation of cell growth and
First author Year Cases/controls ratio 95% CI Ratio and 95% CI
Barrett-Connor 1990 59/945 0.95 (0.85–1.06)
Hsing 1993 98/98 1.02 (0.89–1.17)
Carter 1995 16/16 0.83 (0.62–1.11)
Gann 1996 222/390 1.02 (0.94–1.10)
Nomura 1996 141/141 1.00 (0.91–1.10)
Guess 1997 106/106 0.99 (0.90–1.09)
Vatten 1997 59/180 0.97 (0.88–1.07)
Dorgan 1998 116/231 0.98 (0.91–1.06)
All studies 817/2107 0.99 (0.95–1.02)
0.6 0.8 1.0 1.2 1.4 1.6
First author Year Cases/controls ratio 95% CI Ratio and 95% CI
Nomura 1996 105/105 1.04 (0.90–1.19)
Guess 1997 104/106 1.01 (0.89–1.14)
Dorgan 1998 116/231 1.03 (0.95–1.11)
All studies 325/442 1.02 (0.96–1.09)
0.6 0.8 1.0 1.2 1.4 1.6
First author Year Cases/controls ratio 95% CI Ratio and 95% CI
Hsing 1993 98/98 1.00 (0.89–1.12)
Gann 1996 222/390 0.97 (0.88–1.07)
Nomura 1996 141/141 1.03 (0.94–1.14)
Vatten 1997 59/180 0.98 (0.88–1.10)
Dorgan 1998 116/231 0.96 (0.88–1.04)
All studies 636/1040 0.98 (0.94–1.03)
0.6 0.8 1.0 1.2 1.4 1.6
First author Year Cases/controls ratio 95% CI Ratio and 95% CI
Gann 1996 222/390 1.06 (0.98–1.14)
Nomura 1996 141/141 1.09 (0.97–1.23)
Guess 1997 106/106 1.02 (0.91–1.16)
Vatten 1997 59/180 1.02 (0.90–1.17)
Dorgan 1998 116/231 1.06 (0.93–1.21)
All studies 644/1048 1.05 (1.00–1.11)
0.6 0.8 1.0 1.2 1.4 1.6
First author Year Cases/controls ratio 95% CI Ratio and 95% CI
Barrett-Connor 1990 59/948 0.98 (0.87–1.10)
Nomura 1996 141/141 1.05 (0.97–1.13)
Dorgan 1998 116/231 0.99 (0.93–1.06)
All studies 316/1320 1.01 (0.97–1.06)
0.6 0.8 1.0 1.2 1.4 1.6
First author Year Cases/controls ratio 95% CI Ratio and 95% CI
Comstock 1993 81/81 0.88 (0.72–1.09)
Dorgan 1998 116/231 1.02 (0.90–1.16)
All studies 197/312 0.98 (0.88–1.10)
0.6 0.8 1.0 1.2 1.4 1.6
Figures 1–6 Ratios of the mean hormone levels between cases and
controls for testosterone, non-SHBG-bound testosterone,
dihydrotestosterone, androstanediol glucuronide, androstenedione and
dehydroepiandrosterone sulphate
1 Testosterone
Test for heterogeneity c2
7 = 0.3; P > 0.1, NS
Test for heterogeneity c2
2 = 0.1; P > 0.1, NS
Test for heterogeneity c2
4 = 1.6; P > 0.1, NS
Test for heterogeneity c2
4 = 0.8; P > 0.1, NS
Test for heterogeneity c2
1 = 1.4; P > 0.1, NS
Test for heterogeneity c2
1 = 1.3; P > 0.1, NS




6 Dehydroepiandrosterone sulphateA quantitative review of sex hormones and prostate cancer 933
British Journal of Cancer (1999) 80(7), 930–934 © 1999 Cancer Research Campaign 
progression from subclinical tumour foci into a clinically-manifest
form. Differences in serum A-diol-g concentrations have also been
observed between racial groups with differential risks for prostate
cancer, with higher levels being found among Caucasian and
African-American men compared with Japanese men (Ross et al,
1992). These hormonal differences could be partly determined by
dietary factors (Adlercreutz, 1990), although they may also have a
strong genetic basis. For example, polymorphisms of the 5a-
reductase(II) gene and the 3-a/b-hydroxysteroid dehydrogenase
(II) gene have been found to be differentially distributed between
populations in relation to prostate cancer risk (Reichardt et al,
1995; Devgan et al, 1997). These genes encode for enzymes
involved in androgen metabolism within prostatic cells and allelic
variants that alter enzymic activity could influence hormone
metabolism and therefore may affect prostate cancer risk.
This is a systematic review of published data. We did not
attempt to uncover unpublished observations or those published in
other languages and it is possible that these may affect our pooled
results. This review has presented results from each study in a
consistent format, using the natural logarithm of the ratio of the
mean concentrations of each hormone between cases and controls
in preference to the differences in absolute concentrations.
However, readers should refer to the original articles for details of
the distribution of hormone values.
Little is known about the determinants of hormone levels and
how they interact with each other to influence cell growth. As
such, the measurements of T should be interpreted with care as T
and SHBG are known to be strongly positively correlated via the
feedback effect of free-T on the hypothalamic–pituitary–gonadal
axis (Gann et al, 1996). Indeed, this study reported a much
stronger association between T and prostate cancer risk once
adjustment for SHBG had been made. As such, the lack of associ-
ation found in this review may actually be confounded by the
effect of SHBG and mask a stronger independent relationship
between T and prostate cancer risk.
Although all studies included cases which were confirmed with
histological examination or medical notes, only three studies
analysed hormone levels according to whether cases were clini-
cally overt cancer or were latent, subclinical prostate cancer
diagnosed following transurethral resection for benign prostatic
hyperplasia (Nomura et al, 1988, 1996; Hsing and Comstock,
1993; Dorgan et al, 1998). Similarly, the prevalence of indolent
prostate tumours that existed amongst the control groups at the
time of follow-up, was also unknown. This is a particular problem
in prostate cancer epidemiology as prostatic carcinomas can be
incidentally found at autopsy in up to 80% of men over the age of
80 (Breslow et al, 1977). Such misclassification will serve to
dilute any association between hormone levels and cancer.
These results suggest that the differences, if any, in circulating
hormone levels between prostate cancer cases and controls are
small. However, this may, in part, be due to significant laboratory
variation which will serve to dilute any association present.
Furthermore, all studies, except Carter et al (1995), measured
hormone levels in a single serum sample some years prior to diag-
nosis. This may lead to regression dilution bias towards the null
due to random variation in hormone levels within individuals over
time. Although a single measurement of circulating serum T and
DHT concentrations is thought to reliably reflect mean annual
androgen concentrations in middle-aged men (Vermeulen and
Verdonck, 1992), little is known about the long-term reliability of
a single serum measurement for other hormones. As such, the
reported values of circulating concentrations of androgen metabo-
lites and their related proteins should be interpreted with caution.
Furthermore, it is difficult to determine to what extent a single
measure reflects a lifetime index of hormone status or long-term
exposure. Hormone status early on in life, such as during adoles-
cence (Ross et al, 1986) or even as early as in utero (Henderson et
First author Year Cases/controls ratio 95% CI Ratio and 95% CI
Nomura 1988 98/98 0.97 (0.89–1.07)
Barrett-Connor 1990 58/919 1.17 (0.94–1.46)
Carter 1995 16/16 1.06 (0.78–1.45)
Gann 1996 222/390 0.94 (0.86–1.03)
Dorgan 1998 116/231 0.93 (0.77–1.12)
All studies 510/1654 0.97 (0.92–1.03)
0.6 0.8 1.0 1.2 1.4 1.6
0.6 0.8 1.0 1.2 1.4 1.6
First author Year Cases/controls ratio 95% CI Ratio and 95% CI
Nomura 1988 98/98 0.94 (0.86–1.03)
Barrett-Connor 1990 59/947 1.02 (0.93–1.11)
Hsing 1993 98/98 0.99 (0.87–1.13)
Dorgan 1998 116/231 1.00 (0.93–1.07)
All studies 371/1374 0.99 (0.95–1.03)
0.6 0.8 1.0 1.2 1.4 1.6
First author Year Cases/controls ratio 95% CI Ratio and 95% CI
Nomura 1988 98/98 0.96 (0.88–1.04)
Barrett-Connor 1990 59/948 0.99 (0.91–1.07)
Hsing 1993 98/98 1.05 (0.95–1.16)
Gann 1996 222/390 0.98 (0.93–1.04)
Dorgan 1998 116/231 1.00 (0.94–1.07)
All studies 592/1765 0.99 (0.96–1.02)
0.6 0.8 1.0 1.2 1.4 1.6
First author Year Cases/controls ratio 95% CI Ratio and 95% CI
Hsing 1993 98/98 1.03 (0.84–1.27)
Carter 1995 16/16 0.75 (0.55–1.03)
All studies 114/114 0.94 (0.79–1.11)
0.6 0.8 1.0 1.2 1.4 1.6
First author Year Cases/controls ratio 95% CI Ratio and 95% CI
Hsing 1993 98/98 1.00 (0.87–1.14)
Gann 1996 222/390 1.02 (0.88–1.19)
All studies 320/488 1.01 (0.91–1.12)
Figures 7–11 Ratio of mean hormone levels between cases and controls
for sex hormone binding globulin, oestrone, oestradiol, luteinising hormone
and prolactin





Test for heterogeneity c2
4 = 3.7; P > 0.1, NS
Test for heterogeneity c2
3 = 1.7; P > 0.1, NS
Test for heterogeneity c2
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Test for heterogeneity c2
1 = 2.7; P > 0.1, NS
Test for heterogeneity c2
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al, 1988), may be markedly different between high- and low-risk
populations, and it may be that differences in circulating hormone
levels at these critical times of development are more relevant to
subsequent prostate cancer risk. It may therefore be more appro-
priate to collect several specimens from an individual over many
years to achieve the necessary sensitivity to detect small differ-
ences in hormone levels.
This quantitative review suggests that there are no large differ-
ences between prostate cancer cases and controls in serum hormone
concentrations measured in samples taken some years prior to diag-
nosis. Serum concentrations of A-diol-g were consistently slightly
higher in men who subsequently went on to develop prostate
cancer, and may reflect higher androgenic activity in these men.
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